Trial Profile
A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of MTX in Patients With Active RA Who Have Failed Previous TNF-α Antagonists
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary) ; Golimumab
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Sanofi
- 15 Jul 2019 Results (n=2887) of post-hoc pooled analysis of eight studies (MOBILITY, NCT01061736; TARGET, NCT01709578; ASCERTAIN, NCT01768572; MONARCH, NCT02332590; ACT11575, NCT01217814; ONE, NCT02121210; COMPARE, NCT01764997; and EASY, NCT02057250) and one open label extension (EXTEND; NCT01146652) assessing long-term safety up to 7 years follow up of sarilumab in rheumatoid arthritis patients, published in the Rheumatology.
- 15 Jun 2019 Results assessing long-term safety from the sarilumab clinical development program from MOBILITY (NCT01061736), TARGET (NCT01709578), ASCERTAIN (NCT01768572), EASY (NCT02057250), COMPARE (NCT01764997), ACT11575 (NCT01217814), MONARCH (NCT02332590), ONE (NCT02121210), and the open-label extension EXTEND (NCT01146652) trials presented at the 20th Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting